慢性淋巴细胞白血病:2017年诊断、风险分层与治疗更新
慢性淋巴细胞白血病(CLL)在西方国家最常见,多见于老年人,临床病程高度可变。诊断依靠血细胞计数、血涂片和免疫表型;Rai和Binet分期系统用于预后评估,del(17p)和TP53突变预示对现有化疗耐药,CLL-IPI可区分不同风险组。治疗上,适合者以氟达拉滨+环磷酰胺+利妥昔单抗为标准;不适合者可选苯丁酸氮芥联合抗CD20抗体或伊布替尼持续治疗;复发时根据无治疗间期是否超过3年决定重复或更换方案。
要点
- 诊断依据血细胞计数、血涂片和循环B淋巴细胞免疫表型(CD5及B细胞标志物)。
- del(17p)和/或TP53突变预示对现有化疗耐药;CLL-IPI可将CLL分为不同风险组。
- 适合患者标准一线为氟达拉滨+环磷酰胺+利妥昔单抗;不适合者可选苯丁酸氮芥联合抗CD20抗体或伊布替尼持续治疗。
核心结论
- 新药(伊布替尼、艾代拉里斯、维奈克拉和奥比妥珠单抗)有潜力显著改善CLL患者结局,但其最佳用法(联合、顺序和持续时间)仍未知,因此CLL患者应尽可能参加临床试验。
研究设计与样本
- 综述:总结慢性淋巴细胞白血病(CLL)的诊断、风险分层和治疗进展。
主要发现
- CLL是西方国家最常见的白血病,通常发生于老年患者,临床病程高度可变。
- 白血病转化由特定基因组改变启动,这些改变损害克隆性B细胞的凋亡。
- 存在Rai和Binet两种预后分期系统,通过体格检查和血细胞计数建立。
- 多种生物学和遗传学标志物也具有预后价值;del(17p)和/或TP53基因突变预测对现有化疗耐药。
- 已开发使用遗传、生物学和临床变量的综合预后评分(CLL-IPI),可将CLL分为非常不同的风险组。
关键数值与推荐
- 诊断通过血细胞计数、血涂片和循环B淋巴细胞免疫表型建立,识别携带CD5抗原和B细胞标志物的克隆性B细胞群体。
- 有活动性或症状性疾病或晚期Binet或Rai分期的患者需要治疗。
- 对于体能适合的患者,氟达拉滨、环磷酰胺和利妥昔单抗的化学免疫治疗仍是当前标准治疗。
- 对于不适合的患者,当前可用证据支持两种一线治疗选择:苯丁酸氮芥联合抗CD20抗体(奥比妥珠单抗或利妥昔单抗或奥法木单抗)或伊布替尼持续治疗。
- 复发时,如果无治疗间期超过3年,可重复初始治疗;如果疾病更早复发,应使用替代药物如苯达莫司汀(联合利妥昔单抗)、阿仑单抗、来那度胺、奥法木单抗、伊布替尼、艾代拉里斯或维奈克拉更换治疗。
临床怎么用
- 有del(17p)或TP53突变的患者可用伊布替尼、维奈克拉或艾代拉里斯联合利妥昔单抗治疗。
- 对于有TP53突变或del(17p)的复发患者,或对化学免疫治疗和新药抑制剂难治的患者,可考虑异基因造血干细胞移植。
局限性
- 新药的最佳用法(联合、顺序和持续时间)仍未知。
- 因此,CLL患者应尽可能在临床试验中接受治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Chronic lymphocytic leukemia (CLL) is the commonest leukemia in western countries. The disease typically occurs in elderly patients and has a highly variable clinical course. Leukemic transformation is initiated by specific genomic alterations that impair apoptosis of clonal B cells. DIAGNOSIS: The diagnosis is established by blood counts, blood smears, and immunophenotyping of circulating B lymphocytes, which identify a clonal B-cell population carrying the CD5 antigen and B-cell markers. PROGNOSIS: Two prognostic staging systems exist, the Rai and Binet staging systems, which are established by physical examination and blood counts. Various biological and genetic markers also have prognostic value. Deletions of the short arm of chromosome 17 (del(17p)) and/or mutations of the TP53 gene predict resistance to available chemotherapies. A comprehensive prognostic score (CLL-IPI) using genetic, biological, and clinical variables has recently been developed allowing to classify CLL into very distinct risk groups. THERAPY: Patients with active or symptomatic disease or with advanced Binet or Rai stages require therapy. For physically fit patients, chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab remains the current standard therapy. For unfit patients, currently available evidence supports two options for a first-line therapy: chlorambucil combined with an anti-CD20 antibody (obinutuzumab or rituximab or ofatumumab) or a continuous therapy with ibrutinib. At relapse, the initial treatment may be repeated, if the treatment-free interval exceeds 3 years. If the disease relapses earlier, therapy should be changed using alternative agents such as bendamustine (plus rituximab), alemtuzumab, lenalidomide, ofatumumab, ibrutinib, idelalisib, or venetoclax. Patients with a del(17p) or TP53 mutation can be treated with ibrutinib, venetoclax, or a combination of idelalisib and rituximab. An allogeneic SCT may be considered in relapsing patients with TP53 mutations or del(17p) or patients that are refractory to chemoimmunotherapy and the novel inhibitors. FUTURE CHALLENGES: The new agents (ibrutinib, idelalisib, venetoclax, and obinutuzumab) hold the potential to significantly improve the outcome of CLL patients. However, their optimal use (in terms of combination, sequence, and duration) remains unknown. Therefore, CLL patients should be treated in clinical trials whenever possible.
引用
- Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017. PMID: 28782884. doi:10.1002/ajh.24826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。